{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:24:12Z","timestamp":1784543052502,"version":"3.55.0"},"reference-count":97,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hepatitis C virus (HCV) infection is a major public health concern, with more than 58 million people chronically infected worldwide. The management of HCV, once the domain of specialists only, has been revolutionized by the advent of direct-acting antiviral therapies. To reduce the burden of HCV in the United States (US), emphasis is now being placed on the involvement of primary care physicians in the management of HCV patients. Inclusion of more primary care providers in the HCV diagnosis and treatment initiatives can assist in achieving the goal of HCV elimination, especially in the medically underserved areas. To actively engage in the management of HCV, primary care providers must understand its epidemiology, risk factors, natural history, current treatment regimen, and potential complications. This manuscript reviews these key areas, along with presenting the cost-effectiveness of treatment and evidence-based guidelines for follow-up care in adults with chronic HCV infection who have undergone HCV treatment. Equipped with this foundational knowledge about HCV management, primary care physicians can play a vital role in eliminating HCV.<\/jats:p>","DOI":"10.3390\/jcm14134801","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T10:03:27Z","timestamp":1751882607000},"page":"4801","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hepatitis C\u2014Everything a Primary Care Physician Needs to Know About Diagnosis, Management, and Follow-Up"],"prefix":"10.3390","volume":"14","author":[{"given":"Sindhuri","family":"Benjaram","sequence":"first","affiliation":[{"name":"Thomas Memorial Hospital, West Virginia University, Charleston, WV 26506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Kapur","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Oakland University, Rochester, MI 48309, USA"},{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"McKay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3108-3729","authenticated-orcid":false,"given":"Mohamad Khaled","family":"Almujarkesh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Advent Health, Orlando, FL 32803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-4532","authenticated-orcid":false,"given":"Kassandra S.","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, TriStar Centennial Medical Center, Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Picardal","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI 48202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0704-6402","authenticated-orcid":false,"given":"Diane","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4148-9597","authenticated-orcid":false,"given":"Prateek","family":"Lohia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"ref_1","first-page":"211","article-title":"Hepatitis C and liver transplantation","volume":"13","author":"Tsoulfas","year":"2009","journal-title":"Hippokratia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrgastro.2015.36","article-title":"Mixed HCV infection and reinfection in people who inject drugs\u2014impact on therapy","volume":"12","author":"Cunningham","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e186371","DOI":"10.1001\/jamanetworkopen.2018.6371","article-title":"Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016","volume":"1","author":"Rosenberg","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/ciad411","article-title":"Estimated Prevalence and Awareness of Hepatitis C Virus Infection Among US Adults: National Health and Nutrition Examination Survey, January 2017\u2013March 2020","volume":"77","author":"Lewis","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","unstructured":"World Health Organization (2023, December 22). Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/273174\/9789241550345-eng.pdf?sequence=1."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.3748\/wjg.v19.i41.6957","article-title":"Transmission of hepatitis C virus: Self-limiting hepatitis or chronic hepatitis?","volume":"19","author":"Saito","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3961\/jpmph.21.151","article-title":"Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination","volume":"54","author":"Brunner","year":"2021","journal-title":"J. Prev. Med. Public Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0065-3527(04)63002-8","article-title":"Novel insights into hepatitis C virus replication and persistence","volume":"63","author":"Bartenschlager","year":"2004","journal-title":"Adv. Virus Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-pharmtox-011112-140254","article-title":"Direct-acting antiviral agents for hepatitis C virus infection","volume":"53","author":"Kiser","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1093\/cid\/ciad344","article-title":"Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review","volume":"77","author":"Martinello","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e25076","DOI":"10.1002\/jia2.25076","article-title":"What do clinicians need to watch for with direct-acting antiviral therapy?","volume":"21","author":"Aghemo","year":"2018","journal-title":"J. Int. AIDS Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103588","DOI":"10.1016\/j.drugpo.2022.103588","article-title":"Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation","volume":"102","author":"Schwarz","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"762","DOI":"10.7326\/0003-4819-144-10-200605160-00010","article-title":"A framework for management of hepatitis C in prisons","volume":"144","author":"Spaulding","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.idc.2018.02.012","article-title":"New Treatments Have Changed the Game: Hepatitis C Treatment in Primary Care","volume":"32","author":"Facente","year":"2018","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1053\/j.gastro.2017.10.016","article-title":"Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers","volume":"153","author":"Rattay","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3122\/jabfm.2019.03.180286","article-title":"Hepatitis C Update and Expanding the Role of Primary Care","volume":"32","author":"Simoncini","year":"2019","journal-title":"J. Am. Board Fam. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1165","DOI":"10.1097\/IPC.0000000000001165","article-title":"A Comprehensive Hepatitis C Treatment Program\u2014An Observational Study of Collaboration Between Infectious Disease Specialists and General Internal Medicine Provider Serving a Majority Black Population","volume":"30","author":"Lohia","year":"2022","journal-title":"Infect. Dis. Clin. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11606-017-4280-y","article-title":"Diagnosis and Management of Hepatitis C Infection in Primary Care Settings","volume":"33","author":"Guss","year":"2018","journal-title":"J. Gen. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: A global systematic review and meta-analysis","volume":"9","author":"Oru","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial","volume":"167","author":"Kattakuzhy","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_23","first-page":"S609","article-title":"June. A.B. Hepatitis c: Everything a primary care physician needs to know about hepatitis c from diagnosis to long term follow up","volume":"39","author":"Majagi","year":"2024","journal-title":"J. Gen. Intern. Med."},{"key":"ref_24","unstructured":"World Health Organization (2023, November 21). Hepatitis C. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_26","unstructured":"Centers for Disease Control and Prevention (2023, November 29). Reduce Reported Rate of Hepatitis C-Related Deaths by 20% or More, Available online: https:\/\/www.cdc.gov\/hepatitis\/policy\/npr\/2022\/reduce-reported-hepatitis-c-deaths.htm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/hep.31756","article-title":"County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005\u20132017","volume":"74","author":"Hall","year":"2021","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet. Infect. Dis."},{"key":"ref_29","first-page":"950","article-title":"Hepatitis B and\/or C co-infection in HIV infected patients: A study in a tertiary care centre from South India","volume":"138","author":"Chandra","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC Recommendations for Hepatitis C Screening Among Adults\u2014United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/428578","article-title":"Prospective evaluation of community-acquired acute-phase hepatitis C virus infection","volume":"40","author":"Cox","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/QAD.0b013e32831940a3","article-title":"Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV","volume":"23","author":"Thomson","year":"2009","journal-title":"AIDS"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/ciu695","article-title":"Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men","volume":"59","author":"Vanhommerig","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","unstructured":"Centers for Disease Control and Prevention (2023, December 01). Clinical Screening and Diagnosis for Hepatitis C, Available online: https:\/\/www.cdc.gov\/hepatitis-c\/hcp\/diagnosis-testing\/index.html."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0973-6247.126683","article-title":"Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays","volume":"8","author":"Gupta","year":"2014","journal-title":"Asian J. Transfus. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.gtc.2015.07.003","article-title":"Natural History of Hepatitis C","volume":"44","author":"Lingala","year":"2015","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s12072-012-9355-6","article-title":"Natural history of HCV infection","volume":"6","author":"Sarin","year":"2012","journal-title":"Hepatol. Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.23315","article-title":"Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial","volume":"51","author":"Everhart","year":"2010","journal-title":"Hepatology"},{"key":"ref_41","first-page":"45","article-title":"Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges","volume":"12","author":"Mari","year":"2021","journal-title":"Adolesc. Health Med. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1478-3231.2006.01430.x","article-title":"Progression to cirrhosis in hepatitis C patients: An age-dependent process","volume":"27","author":"Pradat","year":"2007","journal-title":"Liver Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-133-8-200010170-00009","article-title":"Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States","volume":"133","author":"Mehta","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","article-title":"A role for hepatitis C virus infection in type II cryoglobulinemia","volume":"327","author":"Agnello","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12072-015-9684-3","article-title":"Hepatitis C virus as a systemic disease: Reaching beyond the liver","volume":"10","author":"Gill","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Phelan, M., and Cook, C. (2014). A treatment revolution for those who can afford it? Hepatitis C treatment: New medications, profits and patients. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-S6-S5"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2014.09.001","article-title":"Is hepatitis C virus eradication around the corner only 25 years after its discovery?","volume":"45","author":"Ippolito","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3748\/wjg.v29.i6.949","article-title":"Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C","volume":"29","author":"Invernizzi","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_49","first-page":"316","article-title":"Hepatitis C in a New Era: A Review of Current Therapies","volume":"42","author":"Kish","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.14740\/gr971w","article-title":"Prevalence of Hepatitis B Reactivation Among Chinese Individuals with Chronic Hepatitis C Treated with Pan-Oral Direct-Acting Antivirals","volume":"11","author":"Lee","year":"2018","journal-title":"Gastroenterol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"296","DOI":"10.14218\/JCTH.2018.00016","article-title":"HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation","volume":"6","author":"Mavilia","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: A systematic review and meta-analysis","volume":"3","author":"Backus","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_53","unstructured":"University of Liverpool (2025, March 10). Interactions with HCV DAAs and Ribavirin. Available online: www.hep-druginteractions.org\/prescribing_resources\/hep-summaries-hcv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","article-title":"High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic","volume":"47","author":"Norton","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s12072-022-10402-y","article-title":"Drug-drug interactions between direct-acting antivirals and co-medications: A territory-wide cohort study","volume":"16","author":"Hui","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1097\/MEG.0000000000002173","article-title":"Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: An analysis of the World Health Organization VigiBase","volume":"33","author":"Hayes","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/jvh.12074","article-title":"Long-term clearance of hepatitis C virus following interferon \u03b1-2b or peginterferon \u03b1-2b, alone or in combination with ribavirin","volume":"20","author":"Manns","year":"2013","journal-title":"J. Viral Hepat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin","volume":"139","author":"Swain","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.15403\/jgld-1284","article-title":"Benefits of curing hepatitis C infection","volume":"23","author":"Marinho","year":"2014","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/jmv.23562","article-title":"Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: Meta-analysis of clinical studies","volume":"85","author":"Fabrizi","year":"2013","journal-title":"J. Med. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1179\/174329111X576698","article-title":"Preventive medication use among persons with limited life expectancy","volume":"19","author":"Maddison","year":"2011","journal-title":"Prog. Palliat. Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archinte.166.6.605","article-title":"Reconsidering medication appropriateness for patients late in life","volume":"166","author":"Holmes","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatology"},{"key":"ref_64","unstructured":"U.S. Senate Committee on Finance (2024, April 10). The Price of Sovaldi and Its Impact on the US Health Care System, Available online: https:\/\/www.finance.senate.gov\/download\/the-price-of-sovaldi-and-its-impact-on-the-us-health-care-system-full-report."},{"key":"ref_65","unstructured":"Silseth, S., and Shaw, H. (2024, May 02). Analysis of Prescription Drugs for the Treatment of Hepatitis C in the United States. Available online: https:\/\/edge.sitecorecloud.io\/millimaninc5660-milliman6442-prod27d5-0001\/media\/Milliman\/PDFs\/2021-Articles\/6-11-21-Analysis-prescription-drugs-treatment-hepatitis-C-US.pdf."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/apt.14271","article-title":"Systematic review: Cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6","volume":"46","author":"He","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02893380","article-title":"Viral hepatitis: New data on hepatitis C infection","volume":"9","author":"Lotz","year":"2003","journal-title":"Pathol. Oncol. Res."},{"key":"ref_68","first-page":"180","article-title":"Liver transplantation in patients with chronic viral hepatitis","volume":"70","author":"Moreno","year":"2005","journal-title":"Rev. Gastroenterol. Mex."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1077558708324299","article-title":"Cost of liver transplantation: A systematic review and meta-analysis comparing the United States with other OECD countries","volume":"66","author":"Ijtsma","year":"2009","journal-title":"Med. Care Res. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/hep.27736","article-title":"Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease","volume":"61","author":"Leidner","year":"2015","journal-title":"Hepatology"},{"key":"ref_71","first-page":"881","article-title":"Role of primary care providers in hepatitis C prevention and care: One step away from evidence-based practice","volume":"60","author":"Artenie","year":"2014","journal-title":"Can. Fam. Physician"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"HCG. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e0135963","DOI":"10.1371\/journal.pone.0135963","article-title":"Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy","volume":"10","author":"Strassl","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3748\/wjg.v13.i32.4287","article-title":"Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C","volume":"13","author":"Stauber","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_75","first-page":"21","article-title":"Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy","volume":"7","author":"Nguyen","year":"2014","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_76","unstructured":"U.S. Food and Drug Administration (2025, June 25). FDA Drug Safety Communication: FDA Warns of Serious Slowing of the Heart Rate When Antiarrhythmic Drug Amiodarone Is Used with Hepatitis C Treatments Containing Sofosbuvir (Harvoni) or Sovaldi in Combination with Another Direct Acting Antiviral Drug, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-serious-slowing-heart-rate-when-antiarrhythmic-drug."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3748\/wjg.v19.i18.2793","article-title":"Sustained virological response: A milestone in the treatment of chronic hepatitis C","volume":"19","author":"Morisco","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_78","unstructured":"AASLD, and IDSA (2025, June 25). Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy. Available online: https:\/\/www.hcvguidelines.org\/evaluate\/monitoring."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cid\/ciw676","article-title":"Late Relapse Versus Hepatitis C Virus Reinfection in Patients with Sustained Virologic Response After Sofosbuvir-Based Therapies","volume":"64","author":"Sarrazin","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of Late Relapse or Reinfection with Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000445330","article-title":"Management of HCV-Associated Liver Cirrhosis","volume":"32","author":"Schneider","year":"2016","journal-title":"Visc. Med."},{"key":"ref_82","first-page":"626","article-title":"Hepatitis C: Diagnosis and Management","volume":"104","author":"Maness","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_83","unstructured":"AASLD, and IDSA (2025, April 10). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available online: https:\/\/www.hcvguidelines.org\/treatment-experienced\/sof-and-elb-grz-failures."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M13-1829","article-title":"Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study","volume":"160","author":"Re","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/0003-4819-158-9-201305070-00604","article-title":"HIV, age, and the severity of hepatitis C virus-related liver disease: A cohort study","volume":"158","author":"Kirk","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected with Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus\/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice","volume":"64","author":"Bhattacharya","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2020.1123","article-title":"Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement","volume":"323","author":"Owens","year":"2020","journal-title":"JAMA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hep.510310328","article-title":"Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women","volume":"31","author":"Conte","year":"2000","journal-title":"Hepatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0168-8278(00)80075-6","article-title":"Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C","volume":"32","author":"Gervais","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_93","unstructured":"AASLD, and IDSA (2025, June 24). HCV in Pregnancy. Available online: https:\/\/www.hcvguidelines.org\/unique-populations\/pregnancy."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s10620-015-3918-z","article-title":"Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES","volume":"61","author":"Rogal","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"60","author":"Fabrizi","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline Factors Associated with Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection","volume":"154","author":"Jiang","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/TP.0000000000001708","article-title":"International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates","volume":"101","author":"Terrault","year":"2017","journal-title":"Transplantation"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4801\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:06:00Z","timestamp":1760033160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":97,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14134801"],"URL":"https:\/\/doi.org\/10.3390\/jcm14134801","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}